相关实验视频

Updated: Jan 10, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

在常规临床实践中,评估与年龄相关的黄斑退化在抗VEGF治疗期间良好的视觉敏度的持续时间

Andrea Gyenes¹, Lilla István¹, András Papp¹

¹Department of Ophthalmology, Semmelweis University, 1085 Budapest, Hungary.

International journal of molecular sciences

|November 27, 2025

概括

针对多个新血管化领域的抗VEGF药物Aflibercept在与年龄相关的黄斑变性 (AMD) 中提供了优越的视力敏度结果,与拉尼比祖马布相比. 这种多领域的方法导致更好的视力维护和可能更少的剂量.

科学领域:

眼科医生眼科眼科
视网膜疾病视网膜疾病
药理学药理学是指药理学的学科.

背景情况:

神经血管与年龄相关的黄斑变性 (nAMD) 是导致视力丧失的主要原因.
抗VEGF (血管内皮生长因子) 疗法是nAMD的标准治疗方法.
不同的抗VEGF药物针对新血管化过程的各个方面.

研究的目的:

为了比较多域抗VEGF药物与单域药物的疗效,在nAMD患者中实现和保持良好的视力敏度.
引入和使用一种新的"范围内时间" (TIR) 度量来评估视力敏度随时间推移的结果.
评估aflibercept在治疗nAMD时是否比拉尼比祖马布具有优势.

主要方法:

对从2015年到2023年用抗VEGF注射治疗的nAMD患者的临床数据库的回顾性分析.
计算"范围内的时间" (TIR),定义为最佳校正视觉敏度 (BCVA) 超过ETDRS 70字母值 (20/40 Snellen敏度) 的时间.
在aflibercept和ranibizumab治疗组之间,视力敏度结果,TIR和注射频率的统计比较.

主要成果:

无论是aflibercept还是ranibizumab,都显著改善了视力敏度,具有可比的基线BCVA.
与拉尼比祖马布相比,Aflibercept治疗的结果是平均TIR显著更高 (60.90天而不是56.55天),并且在下一次诊所访问时获得>70个ETDRS字母的可能性增加了10%,相比于拉尼比祖马布.
对aflibercept (72.15天) 来说,注射之间的平均时间比 ranibizumab (67.22天) 长,这表明可能需要更少的剂量.

结论:

针对多个新血管化领域的抗VEGF药物,如阿弗利塞普特,在维持良好的视力敏度方面具有显著的优势.
阿弗利布雷塞普治疗与改善视力敏度的维持有关,并可能允许与拉尼比祖马布相比更少的频率管理.
这些发现支持使用多域抗VEGF化合物,以提高治疗与年龄相关的黄斑退化症的疗效.

关键词:

一个自由的接受.这是一种反-VEGF的药物.nAMD 的意思是拉尼比祖马布拉尼尼比祖马布拉尼这是一个门值.时间在范围

更多相关视频

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...